Of these 3.6 million beneficiaries, 1.9 million also had diabetes (other than Type 1) and may already have been eligible for Medicare coverage of GLP-1s as diabetes treatments prior to the FDAs approval of the new use of Wegovy
Anti-obesity activity of the marine carotenoid fucoxanthin
were like, Weve never heard of [CJNG]. They didnt think they were important. Partly as a result, Moris investigation had difficulty gaining traction
Examples (link each to a blog or medical info page): Phentermine Lomaira Diethylproprion Qsymia (phentermine/topiramate) Contrave (bupropion/naltrexone) Which Oral Medications Do We Offer
In drug development, a compounds effect on metabolism and the microbiota should be a critical part of pharmacodynamic evaluation
These should be the main considerations for food and drinks manufacturers when it comes to developing NPD and R&D strategies in a GLP-1 age. For more on Kantars Global and US GLP-1 studies, as well as the new Life After GLP-1 study, click here.